AbbVie Presents R&D Pipeline Update
Bitget2026/10/30 14:02- AbbVie added Phase 3 programs for ABBV-1480 with chemotherapy in first-line NSCLC and etentamig combinations in multiple myeloma.
- Etentamig monotherapy for third-line multiple myeloma is submitted for regulatory review, with approval anticipated in 2027.
- Rinvoq regulatory submissions for hidradenitis suppurativa and systemic lupus erythematosus are expected in 2027.
- Epkinly with R-CHOP in first-line DLBCL completed its Phase 3 readout; regulatory approval is anticipated in 2027.
- ABBV-243's Phase 1 inflammatory bowel disease program was discontinued.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
